Literature DB >> 22740110

Aspirin resistance: current status and role of tailored therapy.

Jonathan Grinstein1, Christopher P Cannon.   

Abstract

Aspirin is integral in the primary and secondary prevention of coronary artery disease and acute coronary syndrome. Given the high clinical importance of aspirin in the management of coronary artery disease, much attention has been directed towards the concept of "aspirin resistance." Unfortunately, the term aspirin resistance is ill-defined in the literature, leading to a large variance in the reported prevalence of this phenomenon. In this review, the current understanding of aspirin resistance is discussed. Commonly used functional and diagnostic tests of platelet function, including their strengths and weakness, are reviewed. We next discuss several proposed mechanisms of aspirin resistance and special high-risk groups at risk for aspirin treatment failure. We then discuss optimal dosing and diagnostic strategies for those populations at risk for aspirin resistance with a focus on tailored aspirin therapy for high-risk groups. Finally, future topics of interest in the field of aspirin resistance are considered.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22740110      PMCID: PMC6652698          DOI: 10.1002/clc.22031

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  15 in total

Review 1.  Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach.

Authors:  Sagar Dugani; Jeffrey M Ames; JoAnn E Manson; Samia Mora
Journal:  Curr Atheroscler Rep       Date:  2018-02-21       Impact factor: 5.113

2.  Aspirin Resistance Predicts Adverse Cardiovascular Events in Patients with Symptomatic Peripheral Artery Disease.

Authors:  Tilak Pasala; Jennifer Soo Hoo; Mary Kate Lockhart; Rehan Waheed; Prasanna Sengodan; Jeffrey Alexander; Sanjay Gandhi
Journal:  Tex Heart Inst J       Date:  2016-12-01

Review 3.  The dilemma of aspirin resistance in obese patients.

Authors:  Devarshi Ardeshna; Sarthak Khare; Pooja S Jagadish; Venugopal Bhattad; Brandon Cave; Rami N Khouzam
Journal:  Ann Transl Med       Date:  2019-09

4.  No significant detectable anti-infection effects of aspirin and statins in chronic obstructive pulmonary disease.

Authors:  Josef Yayan
Journal:  Int J Med Sci       Date:  2015-03-02       Impact factor: 3.738

5.  Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease.

Authors:  Sanne Bøjet Larsen; Erik Lerkevang Grove; Søs Neergaard-Petersen; Morten Würtz; Anne-Mette Hvas; Steen Dalby Kristensen
Journal:  PLoS One       Date:  2015-05-18       Impact factor: 3.240

Review 6.  Aspirin resistance and promoting blood circulation and removing blood stasis: current situation and prospectives.

Authors:  Jie Wang; Xingjiang Xiong; Bo Feng
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-18       Impact factor: 2.629

Review 7.  Antiplatelet treatment in the primary prophylaxis of cardiovascular disease in patients with arterial hypertension.

Authors:  Angelika Osińska; Maciej Osiński; Aleksandra Krasińska; Beata Begier-Krasińska
Journal:  Kardiochir Torakochirurgia Pol       Date:  2017-06-30

8.  Association of GPIa and COX-2 gene polymorphism with aspirin resistance.

Authors:  Hui Wang; Xiaoxin Sun; Wanli Dong; Xiuying Cai; Yun Zhou; Youtao Zhang; Weijian Jiang; Qi Fang
Journal:  J Clin Lab Anal       Date:  2017-09-26       Impact factor: 2.352

Review 9.  The association of four common polymorphisms from four candidate genes (COX-1, COX-2, ITGA2B, ITGA2) with aspirin insensitivity: a meta-analysis.

Authors:  Zhiyuan Weng; Xiaobo Li; Yuqiong Li; Jinxiu Lin; Feng Peng; Wenquan Niu
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

10.  Platelet content of nitric oxide synthase 3 phosphorylated at Serine 1177 is associated with the functional response of platelets to aspirin.

Authors:  Javier Modrego; Luis Azcona; Naiara Martín-Palacios; José J Zamorano-León; Antonio Segura; Pablo Rodríguez; Reddy Guerra; Juan Tamargo; Carlos Macaya; Antonio J López-Farré
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.